Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Solid cancers after allogeneic hematopoietic cell transplantation.

Rizzo JD, Curtis RE, Socié G, Sobocinski KA, Gilbert E, Landgren O, Travis LB, Travis WD, Flowers ME, Friedman DL, Horowitz MM, Wingard JR, Deeg HJ.

Blood. 2009 Jan 29;113(5):1175-83. doi: 10.1182/blood-2008-05-158782. Epub 2008 Oct 29.

2.

Risk of secondary solid malignancies after allogeneic hematopoietic stem cell transplantation and preventive strategies.

Adhikari J, Sharma P, Bhatt VR.

Future Oncol. 2015;11(23):3175-85. doi: 10.2217/fon.15.252. Epub 2015 Nov 9. Review.

PMID:
26551415
4.

Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.

Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J, Deliliers GL, Martino R, Russell N, Van Biezen A, Michallet M, Niederwieser D; Chronic Leukemia Working Party of the EBMT.

Leukemia. 2003 May;17(5):841-8. Review.

PMID:
12750695
5.

Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Düsseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria.

Burdach S, van Kaick B, Laws HJ, Ahrens S, Haase R, Körholz D, Pape H, Dunst J, Kahn T, Willers R, Engel B, Dirksen U, Kramm C, Nürnberger W, Heyll A, Ladenstein R, Gadner H, Jürgens H, Go el U.

Ann Oncol. 2000 Nov;11(11):1451-62. Review.

PMID:
11142486
6.

Oral malignancies following HSCT: graft versus host disease and other risk factors.

Demarosi F, Lodi G, Carrassi A, Soligo D, Sardella A.

Oral Oncol. 2005 Oct;41(9):865-77. Epub 2005 Apr 14. Review.

PMID:
16084755
7.

[Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].

Michallet M, Dhedin N, Michallet AS.

Bull Cancer. 2001 Sep;88(9):908-26. Review. French.

8.
9.

Longterm followup and quality of life after hematopoietic stem cell transplantation.

Sullivan KM.

J Rheumatol Suppl. 1997 May;48:46-52. Review.

PMID:
9150118
10.

Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.

Pérez-Simón JA, Caballero D, Diez-Campelo M, Lopez-Pérez R, Mateos G, Cañizo C, Vazquez L, Vidriales B, Mateos MV, Gonzalez M, San Miguel JF.

Leukemia. 2002 Aug;16(8):1423-31. Review.

Supplemental Content

Support Center